Metabolomycs
Private Company
Funding information not available
Overview
Founded in 2018, Metabolomycs is a private diagnostics company leveraging advanced mass spectrometry-based metabolomics to develop biochemical signatures for disease detection and prognostication. The company has a strong research foundation, with numerous peer-reviewed publications in oncology and metabolic diseases, and is transitioning this research into a clinical diagnostic test. Its core value proposition is enabling earlier, more personalized interventions by identifying metabolic dysregulations before overt disease manifests.
Technology Platform
Quantitative tandem mass spectrometry-based metabolomics platform for identifying disease-specific biochemical signatures ('inborn-like errors of metabolism').
Opportunities
Risk Factors
Competitive Landscape
Metabolomycs competes in the metabolomics diagnostics space against larger, established diagnostic companies (e.g., Quest, LabCorp) developing omics tests, as well as numerous venture-backed startups in the multi-omics and longevity testing arena (e.g., Nightingale Health, Omix). Its differentiation lies in its specific focus on quantitative, targeted mass spectrometry and its research pedigree in oncology biomarker discovery.